
Middle East and Africa Hepatitis B Infection Market
Description
Middle East and Africa Hepatitis B Infection Market
The Middle East and Africa hepatitis B infection market is expected to reach USD 2.21 billion by 2031 from USD 1.47 billion in 2023, growing at a CAGR of 5.2% in the forecast period of 2024 to 2031.
Middle East and Africa Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa)- Industry Trends and Forecast to 2031
Overview of Middle East and Africa Hepatitis B Infection Market Dynamics:
Driver
• Increasing prevalence of hepatitis B infections
Restraint
• Side effects and drug resistance
Opportunity
• Advanced research and development for clinical trials
Market Players:
The key market players operating in the Middle East and Africa hepatitis B infection market are listed below:
• Gilead Sciences, Inc.
• GSK plc
• Dynavax Technologies
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb
Table of Contents
169 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Middle East And Africa Hepatitis B Infection Market
- 1.4 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Therapeutics Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insight
- 4.1 Pestal Analysis
- 4.2 Porter Five Forces
- 5 Middle East And Africa Hepatitis B Infection Market: Regulations
- 5.1 Regulatory Authorities In The Asia-pacific Region
- 5.2 North America Regulatory Scenario
- 5.3 Europe Regulatory Scenario
- 5.4 Middle East And Africa Regulatory Scenario
- 5.5 South America Regulatory Scenario
- 6 Pipeline Analysis
- 7 Epidemiliogy
- 8 Market Overview
- 8.1 Drivers
- 8.1.1 Increasing Prevalence Of Hepatitis B Infections
- 8.1.2 Technological Advancements In Diagnostics
- 8.1.3 Development Of Combination Therapies For Hepatitis B
- 8.1.4 Strategic Initiatives By Companies For Hepatitis B Infection
- 8.2 Restraints
- 8.2.1 Side Effects And Drug Resistance
- 8.2.2 Insufficient Vaccine Coverage For Hepatitis B Infection
- 8.3 Opportunity
- 8.3.1 Rising New Drug Releases And Increasing New Drug Permits For Hepatitis B
- 8.3.2 Government Programs To Raise Awareness Of Hepatitis B Infection
- 8.3.3 Advanced Research And Development For Clinical Trials
- 8.4 Challenges
- 8.4.1 The Cost Of Hepatitis B Treatments Is High
- 8.4.2 Stringent Regulatory Policies And Regional Disparities In Treatment Access
- 9 Middle East And Africa Hepatitis B Infection Market, By Type
- 9.1 Overview
- 9.2 Chronic
- 9.3 Acute
- 10 Middle East And Africa Hepatitis B Infection Market, By Treatment
- 10.1 Overview
- 10.2 Vaccine
- 10.2.1 Hospital Pharmacies
- 10.2.2 Drugs Stores And Retail Pharmacies
- 10.2.3 Online Pharmacies
- 10.3 Antiviral Drugs
- 10.3.1 Tenofovir Alafenamide Fumarate (Taf)
- 10.3.2 Tenofovir Disoproxil Fumarate (Tdf)
- 10.3.3 Entecavir
- 10.3.4 Others
- 10.4 Immune Modulator Drugs
- 10.4.1 Pegylated Interferon
- 10.4.2 Interferon Alpha
- 10.5 Surgery
- 11 Middle East And Africa Hepatitis B Infection Market, By Region
- 11.1 Middle East And Africa
- 11.1.1 South Africa
- 11.1.2 Saudi Arabia
- 11.1.3 Egypt
- 11.1.4 Kuwait
- 11.1.5 Qatar
- 11.1.6 U.A.E
- 11.1.7 Oman
- 11.1.8 Bahrain
- 11.1.9 Rest Of Middle East And Africa
- 12 Middle East And Africa Hepatitis B Treatment Market: Company Landscape
- 12.1 Company Share Analysis: Middle East And Africa
- 13 Swot Analysis
- 14 Company Profile
- 14.1 Gilead Sciences, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Revenue Analysis
- 14.1.3 Company Share Analysis
- 14.1.4 Product Portfolio
- 14.1.5 Recent Development
- 14.2 Glaxosmithkline Plc
- 14.2.1 Company Snapshot
- 14.2.2 Revenue Analysis
- 14.2.3 Company Share Analysis
- 14.2.4 Product Portfolio
- 14.2.5 Recent Development
- 14.3 Dynavax Technologies Corporation
- 14.3.1 Company Snapshot
- 14.3.2 Revenue Analysis
- 14.3.3 Company Share Analysis
- 14.3.4 Product Portfolio
- 14.3.5 Recent Developments
- 14.4 F. Hoffman-la Roche Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Company Share Analysis
- 14.4.4 Product Portfolio
- 14.4.5 Recent Developments
- 14.5 Bristol-myers Squibb Company
- 14.5.1 Company Snapshot
- 14.5.2 Revenue Analysis
- 14.5.3 Company Share Analysis
- 14.5.4 Product Portfolio
- 14.5.5 Recent Developments
- 14.6 Arrowhead Pharmaceuticals, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Revenue Analysis
- 14.6.3 Product Portfolio
- 14.6.4 Recent Developments
- 14.7 Arbutus Biopharma
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Updates
- 14.8 Aurobindo Pharma
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Updates
- 14.9 Lupin Pharmaceuticals, Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Product Portfolio
- 14.9.3 Recent Updates
- 14.10 Merck & Co., Inc.,
- 14.10.1 Company Snapshot
- 14.10.2 Revenue Analysis
- 14.10.3 Product Portfolio
- 14.10.4 Recent Developments
- 14.11 Novartis Ag
- 14.11.1 Company Snapshot
- 14.11.2 Revenue
- 14.11.3 Product Portfolio
- 14.11.4 Recent Development
- 14.12 Teva Pharmaceutical Industries
- 14.12.1 Company Snapshot
- 14.12.2 Product Portfolio
- 14.12.3 Recent Developments
- 14.13 Zydus Pharmaceuticals, Inc.
- 14.13.1 Company Snapshot
- 14.13.2 Product Portfolio
- 14.13.3 Revenue
- 14.13.4 Recent Development
- 15 Questionnaire
- 16 Related Reports
- Table 1 Middle East And Africa Clinical Trial And Pipeline A-lysis As Per The Company
- Table 2 Distribution Of Products Or Projects By Phase
- Table 3 Country Wise Epidemiology For Hepatitis B
- Table 4 Cost Of Hepatitis B Medications: Brand Vs. Generic Prices
- Table 5 Middle East And Africa Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 6 Middle East And Africa Chronic In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 7 Middle East And Africa Acute In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 8 Middle East And Africa Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 9 Middle East And Africa Vaccine In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 10 Middle East And Africa Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 11 Middle East And Africa Antiviral Drugs In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 12 Middle East And Africa Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 13 Middle East And Africa Immune Modulator Drugs In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 14 Middle East And Africa Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 15 Middle East And Africa Surgery In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 16 Middle East And Africa Hepatitis B Infection Market, By Country, 2022-2031 (Usd Million)
- Table 17 Middle East And Africa Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 18 Middle East And Africa Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 19 Middle East And Africa Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 20 Middle East And Africa Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 21 Middle East And Africa Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 22 South Africa Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 23 South Africa Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 24 South Africa Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 25 South Africa Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 26 South Africa Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 27 Saudi Arabia Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 28 Saudi Arabia Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 29 Saudi Arabia Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 30 Saudi Arabia Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 31 Saudi Arabia Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 32 Egypt Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 33 Egypt Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 34 Egypt Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 35 Egypt Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 36 Egypt Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 37 Kuwait Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 38 Kuwait Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 39 Kuwait Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 40 Kuwait Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 41 Kuwait Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 42 Qatar Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 43 Qatar Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 44 Qatar Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 45 Qatar Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 46 Qatar Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 47 U.A.E Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 48 U.A.E Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 49 U.A.E Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 50 U.A.E Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 51 U.A.E Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 52 Oman Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 53 Oman Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 54 Oman Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 55 Oman Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 56 Oman Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 57 Bahrain Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 58 Bahrain Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 59 Bahrain Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 60 Bahrain Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 61 Bahrain Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 62 Rest Of Middle East And Africa Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Figure 1 Middle East And Africa Hepatitis B Infection Market: Segmentation
- Figure 2 Middle East And Africa Hepatitis B Infection Market: Data Triangulation
- Figure 3 Middle East And Africa Hepatitis B Infection Market: Droc Analysis
- Figure 4 Middle East And Africa Hepatitis B Infection Market: Middle East And Africa Vs Regional Market Analysis
- Figure 5 Middle East And Africa Hepatitis B Infection Market: Company Research Analysis
- Figure 6 Middle East And Africa Hepatitis B Infection Market: Multivariate Modelling
- Figure 7 Middle East And Africa Hepatitis B Infection Market: Interview Demographics
- Figure 8 Middle East And Africa Hepatitis B Infection Market: Dbmr Market Position Grid
- Figure 9 Middle East And Africa Hepatitis B Infection Market: Vendor Share Analysis
- Figure 10 Middle East And Africa Hepatitis B Infection Market: Segmentation
- Figure 11 Two Segments Comprise The Middle East And Africa Hepatitis B Infection Market, By Type
- Figure 12 Executive Summary
- Figure 13 Strategic Decisions
- Figure 14 Middle East And Africa Hepatitis B Infection Market
- Figure 15 Chronic Segment Is Expected To Account For The Largest Share Of The Middle East And Africa Hepatitis B Infection Market In 2024 & 2031
- Figure 16 Droc Analysis
- Figure 17 Burden Of Hbv Infection In The General Population By Who Region, 2019
- Figure 18 Middle East And Africa Hepatitis B Infection Market: By Type, 2023
- Figure 19 Middle East And Africa Hepatitis B Infection Market: By Type, 2024-2031 (Usd Million)
- Figure 20 Middle East And Africa Hepatitis B Infection Market: By Type, Cagr (2024-2031)
- Figure 21 Middle East And Africa Hepatitis B Infection Market: By Type, Lifeline Curve
- Figure 22 Middle East And Africa Hepatitis B Infection Market: By Treatment, 2023
- Figure 23 Middle East And Africa Hepatitis B Infection Market: By Treatment, 2024-2031 (Usd Million)
- Figure 24 Middle East And Africa Hepatitis B Infection Market: By Treatment, Cagr (2024-2031)
- Figure 25 Middle East And Africa Hepatitis B Infection Market By Treatment, Lifeline Curve
- Figure 26 Middle East And Africa Hepatitis B Infection Market, Snapshot
- Figure 27 Middle East And Africa Hepatitis B Treatment Market: Company Share 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.